NCT04837209: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor, Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: If tumor is PD-L1+, patient must have progressed on immune-checkpoint inhibitor (e.g. Keytruda, Tecentriq); Patient must have at least one tumor for which radiation therapy is considered clinically appropriate
Exclusions: Patients with more than 2 prior lines of systemic therapy for metastatic disease; Patients with known germline (hereditary) or somatic BRCA mutation-positive status; Patients with known active brain metastases or leptomeningeal disease – see trial for details

Comments are closed.

Up ↑